Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by PLA2G7 is a secreted enzyme that catalyzes the degradation of platelet-activating factor to biologically inactive products. Additionally we are shipping PLA2G7 Kits (7) and PLA2G7 Proteins (2) and many more products for this protein.
Showing 10 out of 16 products:
Human Polyclonal PLA2G7 Primary Antibody for IF (p), IHC (p) - ABIN686722
Rosing, Fobker, Kannenberg, Gunia, DellAquila, Kwiecien, Stypmann, Nofer: Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. in Atherosclerosis 2013
Show all 2 references for ABIN686722
Lp-PLA2 (show Lp-PLA2 Antibodies) activity in Japanese men aged 50-79 years was associated significantly and positively with IMT and plaque in the carotid artery but Mendelian randomization did not support that Lp-PLA2 (show Lp-PLA2 Antibodies) is a causative factor for subclinical atherosclerosis.
279Val-->Phe Polymorphism of Lp-PLA2 (show Lp-PLA2 Antibodies) may lead to decrease the enzymatic activity via changes of folding kinetics and recognition to its substrate.
Increased plasma Lp-PLA2 (show Lp-PLA2 Antibodies) activity portends increased risk of resistant hypertension.
These findings suggest that plasma PAF (show KIAA0101 Antibodies) may be a potential biomarker for predicting poor bone health in postmenopausal women.
Studied whether the level of Lp-PLA2 (show Lp-PLA2 Antibodies) is associated with subclinical atherosclerosis in patients with rheumatoid arthritis.
Higher Lp-PLA2 (show Lp-PLA2 Antibodies) mass and activity were associated with development of both incident clinical peripheral arterial disease and low ankle brachial index.
A V279F loss-of-function variant in the PLA2G7 (show Lp-PLA2 Antibodies) gene resulting in 50% lower activity for each copy of the variant, is common in East Asians and associated with risk of Vascular diseases.
It is assumed that Lp-PLA2 (show Lp-PLA2 Antibodies) is involved in vascular calcification and that dp-ucMGP is a more appropriate biomarker of residual risk than Lp-PLA2 (show Lp-PLA2 Antibodies) itself.
Cytosolic phospholipase A2 (show PLA2G4A Antibodies) modulates TLR2 (show TLR2 Antibodies) signaling in synoviocytes.
Lipoprotein associated phospholipase A2 activity and apolipoprotein C3 (show APOC3 Antibodies) loss-of-function variants are involved in cardiovascular disease
The protein encoded by this gene is a secreted enzyme that catalyzes the degradation of platelet-activating factor to biologically inactive products. Defects in this gene are a cause of platelet-activating factor acetylhydrolase deficiency. Two transcript variants encoding the same protein have been found for this gene.
, 2-acetyl-1-alkylglycerophosphocholine esterase
, LDL-associated phospholipase A2
, PAF 2-acylhydrolase
, PAF acetylhydrolase
, platelet-activating factor acetylhydrolase
, plasma PAF acetylhydrolase
, group-VIIA phospholipase A2
, lipoprotein-associated phospholipase A2